Shanqi Guo

923 total citations
35 papers, 686 citations indexed

About

Shanqi Guo is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Shanqi Guo has authored 35 papers receiving a total of 686 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 12 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in Shanqi Guo's work include Cancer-related molecular mechanisms research (8 papers), Lymphoma Diagnosis and Treatment (5 papers) and Multiple Myeloma Research and Treatments (4 papers). Shanqi Guo is often cited by papers focused on Cancer-related molecular mechanisms research (8 papers), Lymphoma Diagnosis and Treatment (5 papers) and Multiple Myeloma Research and Treatments (4 papers). Shanqi Guo collaborates with scholars based in China, United States and Australia. Shanqi Guo's co-authors include Xingkang Jiang, Baojie Ma, Yangyi Zhang, Yong Xu, Yingjie Jia, Xiaojiang Li, Shuo Wang, Xiaojian Li, Lili Wang and Wanqing Li and has published in prestigious journals such as Blood, Hepatology and Cancer Research.

In The Last Decade

Shanqi Guo

31 papers receiving 677 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shanqi Guo China 13 453 384 198 83 78 35 686
Alessandro Sacco Italy 10 478 1.1× 398 1.0× 432 2.2× 115 1.4× 46 0.6× 17 779
Jingping Ge China 18 546 1.2× 417 1.1× 101 0.5× 71 0.9× 19 0.2× 40 719
Luyang Wang China 8 264 0.6× 180 0.5× 224 1.1× 102 1.2× 24 0.3× 12 454
Yanmeng Li China 13 186 0.4× 150 0.4× 143 0.7× 139 1.7× 53 0.7× 43 496
Zhuan Feng China 10 299 0.7× 214 0.6× 235 1.2× 55 0.7× 24 0.3× 14 521
Yasutoshi Yamada Japan 13 726 1.6× 649 1.7× 139 0.7× 63 0.8× 21 0.3× 39 937
Donghua Gu China 13 385 0.8× 202 0.5× 95 0.5× 79 1.0× 22 0.3× 23 518
Sercan Ergün Türkiye 14 445 1.0× 413 1.1× 35 0.2× 40 0.5× 52 0.7× 43 643

Countries citing papers authored by Shanqi Guo

Since Specialization
Citations

This map shows the geographic impact of Shanqi Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shanqi Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shanqi Guo more than expected).

Fields of papers citing papers by Shanqi Guo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shanqi Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shanqi Guo. The network helps show where Shanqi Guo may publish in the future.

Co-authorship network of co-authors of Shanqi Guo

This figure shows the co-authorship network connecting the top 25 collaborators of Shanqi Guo. A scholar is included among the top collaborators of Shanqi Guo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shanqi Guo. Shanqi Guo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Liu, Jinming, et al.. (2025). Risk Signals of Antibody-Drug Conjugates in Bladder Cancer: A Real-World FAERS Study. Clinical Epidemiology. Volume 17. 995–1009.
4.
Liu, Wei, Shanqi Guo, Yong Wang, et al.. (2024). Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤60 years: real-world data from a single urological center over a 10-year period. Translational Andrology and Urology. 13(11). 2408–2418. 1 indexed citations
5.
Jiang, Xingkang, et al.. (2023). Exosomal lincROR Promotes Docetaxel Resistance in Prostate Cancer through a β-catenin/HIF1α Positive Feedback Loop. Molecular Cancer Research. 21(5). 472–482. 21 indexed citations
6.
Liu, Xiaodi, et al.. (2023). Nanobodies: a new potential for prostate cancer treatment. Journal of Cancer Research and Clinical Oncology. 149(9). 6703–6710. 7 indexed citations
7.
Guo, Shanqi, Yangyi Zhang, Yangyi Zhang, et al.. (2021). LncRNA PCA3 promotes antimony-induced lipid metabolic disorder in prostate cancer by targeting MIR-132-3 P/SREBP1 signaling. Toxicology Letters. 348. 50–58. 18 indexed citations
8.
Zhang, Yangyi, Shanqi Guo, Shuo Wang, et al.. (2021). LncRNA OIP5-AS1 inhibits ferroptosis in prostate cancer with long-term cadmium exposure through miR-128-3p/SLC7A11 signaling. Ecotoxicology and Environmental Safety. 220. 112376–112376. 140 indexed citations
9.
Li, Wenjie, Xiaodi Liu, Zhao Liu, et al.. (2020). Prostate cancer: a risk factor for COVID-19 in males?. Medicine. 99(43). e22591–e22591. 5 indexed citations
10.
Jiang, Xingkang, Shanqi Guo, Yangyi Zhang, et al.. (2019). LncRNA NEAT1 promotes docetaxel resistance in prostate cancer by regulating ACSL4 via sponging miR-34a-5p and miR-204-5p. Cellular Signalling. 65. 109422–109422. 100 indexed citations
11.
Xu, Dan, et al.. (2018). Dosimetry study of 18F-FMISO + PET/CT hypoxia imaging guidance on intensity-modulated radiation therapy for non-small cell lung cancer. Clinical & Translational Oncology. 20(10). 1329–1336. 13 indexed citations
12.
Guo, Shanqi, et al.. (2017). The protective role of TET2 in erythroid iron homeostasis against oxidative stress and erythropoiesis. Cellular Signalling. 38. 106–115. 13 indexed citations
13.
14.
Santini, Valeria, Ana G. Almeida, Aristoteles Giagounidis, et al.. (2015). 116 THE EFFECT OF LENALIDOMIDE ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH MDS: RESULTS FROM THE MDS-005 TRIAL. Leukemia Research. 39. S60–S60. 1 indexed citations
15.
16.
Xia, Bing, Chen Tian, Shanqi Guo, et al.. (2014). c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia. Leukemia Research. 39(1). 92–99. 67 indexed citations
17.
Zhao, Haifeng, Le Zhang, Shanqi Guo, et al.. (2014). Downregulated expression of Dicer1 predicts inferior survival in primary gastrointestinal diffuse large B-cell lymphoma treated with CHOP-like regimen and rituximab. Medical Oncology. 31(10). 206–206. 4 indexed citations
18.
Zhang, Yizhuo, Shanqi Guo, Le Zhang, et al.. (2013). Prognostic factors associated with solitary plasmacytoma. OncoTargets and Therapy. 6. 1659–1659. 20 indexed citations
19.
Guo, Shanqi, Hongliang Yang, Yong Yu, et al.. (2013). Bcl-2 expression is associated with poor prognosis of solitary plasmacytoma of bone. Annals of Hematology. 93(3). 471–477. 7 indexed citations
20.
Guo, Shanqi, et al.. (2012). Effects of Iso-osmotic Ca(NO_3)_2 and NaCl Stress on Chloroplast Ultra-structure and Photosynthesis in Cucumber leaves. Zhongguo shucai. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alessandro Sacco Breakdown of academic impact, for papers by Jingping Ge Breakdown of academic impact, for papers by Luyang Wang Breakdown of academic impact, for papers by Yanmeng Li Breakdown of academic impact, for papers by Zhuan Feng Breakdown of academic impact, for papers by Yasutoshi Yamada Breakdown of academic impact, for papers by Donghua Gu Breakdown of academic impact, for papers by Sercan Ergün
Rankless by CCL
2026